NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Biodexa Pharmaceuticals Plc (BDRX) Stock Analysis

Biodexa Pharmaceuticals Plc (BDRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BDRX

$0.85

+$0.05 (+6.27%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BDRX with… →

BDRX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.78
Previous Close
$0.80
Day's Range
0.77–0.86
52-Week Range
0.76–59.40
Volume
104.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$872.65K
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−67.57
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.03M
1-Year Return
−85.15%
Dividend and dates
Avg Volume
482.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BDRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−62.64%
2025−94.98%

As of September 4, 2026.

BDRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.38M—
2024$0.00−$5.73M—
2023$381.00K−$7.08M−1858.0%
2022$699.00K−$7.66M−1095.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00−$3.96M−$8.65M−$6.38M—
2024$0.00−$5.44M−$9.20M−$5.73M—
2023$381.00K−$3.69M−$8.01M−$7.08M−1858.0%
2022$699.00K−$4.41M−$8.93M−$7.66M−1095.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BDRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricBDRXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Biodexa Pharmaceuticals Plc (BDRX) at $872.65K. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 11.

BDRX last closed at $0.85 on September 4, 2026. That is +$0.05 (+6.27%) against the previous close. Over the past 52 weeks the price has ranged from $0.76 to $59.40. The latest close sits 12.32% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $6.38M. Profit margin runs at 0%. Trailing earnings per share are −67.57.

Across the 4 fiscal years on file, revenue moves from $699.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.19. Daily returns over the trailing 1 year annualize to a volatility of 635.24%. The trailing one-year price return is −85.15%. The stored price history starts on January 10, 2025, and the total return since then is −98.12%.

Growth & Income

No dividend is on file for BDRX.

So far in 2026 the price is −62.64%. The record holds one complete calendar year, 2025, which returned −94.98%.

Peer Comparison

Biodexa Pharmaceuticals Plc (BDRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biodexa Pharmaceuticals Plc BDRX $872.65K —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Biodexa Pharmaceuticals Plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Visit website →